Ibrutinib

Ibrutinib Reactions 1680, p162 - 2 Dec 2017 Mild fatigue, easy bruising and atrial fibrillation: 2 case reports In a case series, two patients were described, out of whom a 73-year-old woman developed mild fatigue and easy bruising and a 77-year-old man developed atrial fibrillation during treatment with ibrutinib [route, time to reactions onsets and outcomes not stated]. Patient 1: A 73-year-old woman, who had a history of B-cell prolymphocytic leukaemia, was started on ibrutinib 420mg daily. She had also received rituximab and enoxaparin. Her treatment course with ibrutinib was complicated by mild fatigue and easy bruising. The treatment with ibrutinib was maintained. She remained on ibrutinib for 15 months. Patient 2: A 77-year-old man, who had a history of B-cell prolymphocytic leukaemia, was started on ibrutinib 420 mg/day. His relevant medical history included coronary artery disease and hypertension. He had also received unspecified antibiotics and steroids, bendamustine and rituximab. His treatment course with ibrutinib was complicated by an episode of atrial fibrillation, which required a brief discontinuation of ibrutinib therapy. Later, ibrutinib was restarted and his constitutional symptoms resolved with therapy. He remained on ibrutinib for 12 months. Author comment: "Therapy was complicated by mild fatigue and easy bruising, not requiring either dose adjustment or interruption." "The treatment course was complicated by an episode of atrial fibrillation which required a brief interruption of ibrutinib therapy." Gordon MJ, et al. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. British Journal of Haematology 179: 501-503, No. 3, Nov 2017. Available from: URL: http://doi.org/10.1111/bjh.14224 - USA 803284481 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ibrutinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/ibrutinib-uBJAwkNu2C
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39093-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p162 - 2 Dec 2017 Mild fatigue, easy bruising and atrial fibrillation: 2 case reports In a case series, two patients were described, out of whom a 73-year-old woman developed mild fatigue and easy bruising and a 77-year-old man developed atrial fibrillation during treatment with ibrutinib [route, time to reactions onsets and outcomes not stated]. Patient 1: A 73-year-old woman, who had a history of B-cell prolymphocytic leukaemia, was started on ibrutinib 420mg daily. She had also received rituximab and enoxaparin. Her treatment course with ibrutinib was complicated by mild fatigue and easy bruising. The treatment with ibrutinib was maintained. She remained on ibrutinib for 15 months. Patient 2: A 77-year-old man, who had a history of B-cell prolymphocytic leukaemia, was started on ibrutinib 420 mg/day. His relevant medical history included coronary artery disease and hypertension. He had also received unspecified antibiotics and steroids, bendamustine and rituximab. His treatment course with ibrutinib was complicated by an episode of atrial fibrillation, which required a brief discontinuation of ibrutinib therapy. Later, ibrutinib was restarted and his constitutional symptoms resolved with therapy. He remained on ibrutinib for 12 months. Author comment: "Therapy was complicated by mild fatigue and easy bruising, not requiring either dose adjustment or interruption." "The treatment course was complicated by an episode of atrial fibrillation which required a brief interruption of ibrutinib therapy." Gordon MJ, et al. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. British Journal of Haematology 179: 501-503, No. 3, Nov 2017. Available from: URL: http://doi.org/10.1111/bjh.14224 - USA 803284481 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off